Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M179,820Revenue $M48,851Net Margin (%)15.9Altman Z-Score2.3
Enterprise Value $M198,372EPS $1.2Operating Margin %25.1Piotroski F-Score6
P/E(ttm)21.9Beneish M-Score-2.7Pre-tax Margin (%)20.0Higher ROA y-yN
Price/Book2.710-y EBITDA Growth Rate %2.3Quick Ratio1.3Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %4.2Current Ratio1.6Lower Leverage y-yY
Price/Free Cash Flow13.2y-y EBITDA Growth Rate %-17.4ROA % (ttm)5.6Higher Current Ratio y-yN
Dividend Yield %3.9PEG5.3ROE % (ttm)13.3Less Shares Outstanding y-yY
Payout Ratio %83.0Shares Outstanding M6,173ROIC % (ttm)17.0Gross Margin Increase y-yY

Gurus Latest Trades with PFE

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEKahn Brothers 2015-12-31 Reduce-0.59%$31.33 - $35.45
($33.17)
$ 29.49-11%Reduce -6.05%1,569,873
PFET Rowe Price Equity Income Fund 2015-12-31 Add0.28%$31.33 - $35.45
($33.18)
$ 29.49-11%Add 15.28%14,525,000
PFEVanguard Health Care Fund 2015-12-31 Reduce-0.25%$31.33 - $35.45
($33.17)
$ 29.49-11%Reduce -29.31%8,872,226
PFECharles Brandes 2015-12-31 Reduce-0.1%$31.33 - $35.45
($33.17)
$ 29.49-11%Reduce -3.82%5,639,537
PFEKen Fisher 2015-12-31 Add0.03%$31.33 - $35.45
($33.18)
$ 29.49-11%Add 1.28%32,334,417
PFEJames Barrow 2015-12-31 Reduce-0.02%$31.33 - $35.45
($33.17)
$ 29.49-11%Reduce -0.76%53,862,996
PFEMario Gabelli 2015-12-31 Reduce$31.33 - $35.45
($33.17)
$ 29.49-11%Reduce -3.16%706,956
PFERichard Pzena 2015-12-31 Add$31.33 - $35.45
($33.17)
$ 29.49-11%Add 0.08%2,161,593
PFELeon Cooperman 2015-09-30 Buy 3.06%$30.82 - $36.15
($33.8)
$ 29.49-13%New holding4,830,595
PFEKahn Brothers 2015-09-30 Reduce-0.59%$30.82 - $36.15
($33.8)
$ 29.49-13%Reduce -5.85%1,671,039
PFEVanguard Health Care Fund 2015-09-30 Reduce-0.46%$30.82 - $36.15
($33.8)
$ 29.49-13%Reduce -35.29%12,550,992
PFEFirst Eagle Investment 2015-09-30 Add0.14%$30.82 - $36.15
($33.8)
$ 29.49-13%Add 41.13%6,090,294
PFECharles Brandes 2015-09-30 Reduce-0.08%$30.82 - $36.15
($33.8)
$ 29.49-13%Reduce -3.16%5,863,701
PFEDavid Dreman 2015-09-30 Reduce-0.05%$30.82 - $36.15
($33.8)
$ 29.49-13%Reduce -74.15%6,443
PFEJames Barrow 2015-09-30 Reduce-0.05%$30.82 - $36.15
($33.8)
$ 29.49-13%Reduce -1.95%54,274,453
PFET Rowe Price Equity Income Fund 2015-09-30 Reduce-0.02%$30.82 - $36.15
($33.8)
$ 29.49-13%Reduce -1.08%12,599,315
PFEMario Gabelli 2015-09-30 Reduce-0.02%$30.82 - $36.15
($33.8)
$ 29.49-13%Reduce -10.96%730,005
PFENWQ Managers 2015-09-30 Reduce-0.01%$30.82 - $36.15
($33.8)
$ 29.49-13%Reduce -0.35%4,357,477
PFEJoel Greenblatt 2015-09-30 Add0.01%$30.82 - $36.15
($33.8)
$ 29.49-13%Add 2.27%1,047,861
PFEKen Fisher 2015-09-30 Add0.01%$30.82 - $36.15
($33.8)
$ 29.49-13%Add 0.35%31,926,879
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CANGIALOSI LORETTA VSr. Vice President, Controller 2015-07-30Sell24,704$35.65-17.28view
OLSON LAURIE JExecutive Vice President 2015-06-11Sell26,000$34.39-14.25view
HILL CHARLES HExecutive Vice President 2015-05-29Sell42,870$34.92-15.55view
SUSMAN SALLYExecutive Vice President 2015-03-12Sell46,179$34-13.26view
READ IAN CChairman & CEO 2015-03-05Sell67,500$34.62-14.82view
Dolsten MikaelPresident R&D 2015-03-05Sell58,298$34.46-14.42view
CANGIALOSI LORETTA VSr. Vice President, Controller 2015-02-13Sell104,000$34.73-15.09view
MADDALUNA ANTHONY JExecutive Vice President 2015-02-12Sell9,000$34.85-15.38view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell80,200$34.23-13.85view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell14,800$34.3-14.02view

Quarterly/Annual Reports about PFE:

    News about PFE:

    Articles On GuruFocus.com
    Kahn Brothers Sells Part of Stake in Pfizer in 4th Quarter Feb 09 2016 
    Is Apple the Next Altria? Feb 02 2016 
    UnitedHealth Likely to Build on Growth in the Health Care Sector Jan 05 2016 
    Third Avenue Management's Annual Report Dec 29 2015 
    5 Guru Picks in Volatile Biotech Industry Dec 23 2015 
    Jim Simons' Top Holdings Include VeriSign, Chipotle Dec 15 2015 
    A Fed Rate Hike: What Investment Options Await You Dec 15 2015 
    Cooperman's Big Bets Include Alphabet, Pfizer Dec 06 2015 
    Leon Cooperman Adds Google Holdings and Buys Pfizer Nov 23 2015 
    What's Lee Ainslie's Angle to Buy Into a Pharmaceutical Stalwart Yielding 3%? Nov 19 2015 

    More From Other Websites
    Pfizer's Biosimilar of Remicade Recommended for Approval Feb 10 2016
    Relypsa: This Biotech Just Released Stunning Data Feb 10 2016
    Why Pfizer (PFE) Stock Is Rising Today Feb 10 2016
    'I would not want to be a cancer patient in England' says Pfizer boss Feb 10 2016
    3 Value Stocks Ready to Outperform Feb 10 2016
    Panel Recommends FDA Approval of Remicade Knockoff Feb 10 2016
    Short Sellers Increase Bets in Major Pharma Feb 10 2016
    5 Safe, Strong Stocks to Add to Your Portfolio in Uncertain Times Feb 10 2016
    AbbVie, Maker of World's No. 1 Drug, Bets Synthetic Biology Startup Can Raise The Bar Feb 10 2016
    1:43 am Pfizer receives FDA committee vote to approve investigational biosimilar infliximab Feb 10 2016
    Panel Recommends FDA Approval of Remicade Knockoff Feb 10 2016
    Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The... Feb 09 2016
    FDA panel backs lower-cost version of J&J's top-selling drug Feb 09 2016
    FDA panel backs lower-cost version of J&J's top-selling drug Feb 09 2016
    Pfizer, Reynolds Among Recession Stock Plays — GE, GM For Recovery Feb 09 2016
    What Investors Can Expect from Healthcare Sector Companies Feb 09 2016
    Why Merrill Lynch Sees Big Upside in Pfizer (and Even More With Allergan) Feb 09 2016
    Pfizer’s Loss of Product Exclusivity Affected Its 4Q15 Revenues Feb 09 2016
    Pfizer Reported 7% Top Line Growth in 4Q15 Feb 09 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    Daniel Seens
    ReplyDaniel Seens - 1 year ago
    PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK